Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane (TEAM)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00036270
First received: May 8, 2002
Last updated: October 6, 2015
Last verified: October 2015
Results First Received: October 30, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Breast Neoplasms
Interventions: Drug: exemestane (Aromasin)
Drug: tamoxifen + exemestane

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Exemestane Exemestane (Aromasin®) 25 milligram (mg) once daily (QD) for 5 years.
Tamoxifen Followed by Exemestane Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.

Participant Flow for 2 periods

Period 1:   Randomized to Study Treatment
    Exemestane   Tamoxifen Followed by Exemestane
STARTED   4904   4875 
COMPLETED   4898   4868 
NOT COMPLETED   6   7 
Withdrawal by Subject                6                7 

Period 2:   Study Treatment to 5 Year Report
    Exemestane   Tamoxifen Followed by Exemestane
STARTED   4898   4868 
Treated   4852   4814 
COMPLETED   2333   1380 
NOT COMPLETED   2565   3488 
Ongoing                1081                736 
Disease- Free Survival (DFS) event                507                447 
Adverse Event                501                782 
Unspecified                277                288 
Treatment refusal                113                208 
Randomized but not treated                46                54 
Protocol Violation                23                91 
Intercurrent illness                17                29 
Too early switch                0                103 
No/too late switch/refusal to switch                0                750 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Exemestane Exemestane (Aromasin®) 25 mg QD for 5 years.
Tamoxifen Followed by Exemestane Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.
Total Total of all reporting groups

Baseline Measures
   Exemestane   Tamoxifen Followed by Exemestane   Total 
Overall Participants Analyzed 
[Units: Participants]
 4898   4868   9766 
Age 
[Units: Years]
Mean (Standard Deviation)
 65  (9)   64  (9)   64  (9) 
Age, Customized 
[Units: Participants]
     
Less than 50 years   171   160   331 
50 to 59 years   1510   1507   3017 
60 to 69 years   1835   1896   3731 
Greater than and equal to 70 years   1382   1305   2687 
Gender 
[Units: Participants]
     
Female   4898   4868   9766 
Male   0   0   0 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years   [ Time Frame: Baseline (Month 0) up to 2.75 years ]

2.  Primary:   Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years   [ Time Frame: Baseline (Month 0) up to 5 years ]

3.  Secondary:   Number of Events for Overall Survival (OS)   [ Time Frame: Baseline (Month 0) up to 5 years ]

4.  Secondary:   Time to New Primary Breast Cancers   [ Time Frame: Baseline (Month 0) up to 5 years ]
  Hide Outcome Measure 4

Measure Type Secondary
Measure Title Time to New Primary Breast Cancers
Measure Description New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).
Time Frame Baseline (Month 0) up to 5 years  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Data was not analyzed due to insufficient number of events reported for the endpoint.

Reporting Groups
  Description
Exemestane Exemestane (Aromasin®) 25 mg QD for 5 years.
Tamoxifen Followed by Exemestane Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.

Measured Values
   Exemestane   Tamoxifen Followed by Exemestane 
Participants Analyzed 
[Units: Participants]
 0   0 
Time to New Primary Breast Cancers       

No statistical analysis provided for Time to New Primary Breast Cancers



5.  Secondary:   Number of Events for Time to Relapse   [ Time Frame: Baseline (Month 0) up to 5 years ]

6.  Secondary:   Number of Participants With New Primary Non-breast Cancers   [ Time Frame: Baseline (Month 0) up to 5 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Overall Survival was reported as number of events which otherwise reported as time.


  More Information